LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Johan Harmenberg has been appointed Chief Medical Officer (CMO) of LIDDS AB. Johan Harmenberg has extensive experience from the pharmaceutical sector and in particular from oncology companies, most recently the Swedish company Oncopeptides. Johan will work part-time for LIDDS and starts immediately.
“I am delighted to have Johan on board. LIDDS is in a growth and expansion momentum and I am convinced Johan will contribute very positively to our growth and development given his excellent and relevant background as Chief Medical Officer in several oncology companies” said Nina Herne, CEO of LIDDS. “This is an important step for the build-up of our organization.
Johan has a strong industrial background and has worked for both smaller start-up companies and large pharmaceutical companies. Previous positions include being CMO and strategic advisor for Oncopeptides, CMO and CEO for Akinion and Axelar and CMO for Algeta. Prior to that Johan held various positions at Medivir, Pharmacia and Astra. He has an MD and PhD from the Karolinska Institute and has also studied at Massachusetts Institute of Technology (MIT) and Stockholm University.
“I am very pleased to have been appointed CMO for development, promoting the development of new oncology products based on LIDDS NanoZolid technology, which I find very interesting ”, commented Johan Harmenberg.
For more information, please contact:
Nina Herne, CEO, Phone: +46 (0)70-714 74 57, Email: email@example.com
LIDDS AB is required to disclose this information pursuant to Nasdaq First North Growth Market – Rulebook. The information was submitted for publication, through the agency of the aforementioned contact person, on November 15, 2021 at 11:00 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, firstname.lastname@example.org, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
SBM Offshore signs FPSO Alexandre de Gusmão contracts30.11.2021 07:00:00 CET | Press release
November 30, 2021 SBM Offshore is pleased to announce it has signed contracts with Petróleo Brasileiro S.A. (Petrobras) for the 22.5 years lease and operation of FPSO Alexandre deGusmão. These contracts follow the signing of the binding Letter of Intent as announced on August 3, 2021. FPSO Alexandre deGusmão will be deployed at the Mero field in the Santos Basin offshore Brazil, approximately 160 kilometers from Arraial do Cabo, Rio de Janeiro state. Mero is a project under Libra Consortium responsibility, in which Petrobras is the operator with 40 percent and with the following partners: Shell Brasil with 20 percent, TotalEnergies with 20 percent, CNODC and CNOOC Limited with 10 percent each, together with Pré-sal Petróleo S.A. (PPSA) as manager of this contract. SBM Offshore is progressing with the design and construction using its industry leading Fast4Ward® program. First oil is expected in 2025. CorporateProfile The Company’s main activities are the design, supply, installation, o
Ultimovacs ASA: Mandatory notification of trade by primary insider29.11.2021 20:15:15 CET | Press release
Oslo, 29 November 2021, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at a price of NOK 114.00 per share, and a closely related party has today bought 1,000 shares in the company at a price of NOK 114.00 per share. Following this transaction, Carlos de Sousa and closely related parties hold 14,056 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachments 20211129 - Ultimovacs Notification of trade - KRT-1500 220211129 - Ultimovacs Notification of trade - KRT-1500 1
PRESS RELEASE: BIGBEN: 2021/22 HALF-YEAR RESULTS29.11.2021 19:24:15 CET | Press release
Bigben Press release Lesquin, 29 November 2021 18:00 hrs Unfavourable comparison basis for HY1 2021/22 : Sales: 124,2 M€ (-8,5%)Current Operating Income: 9,9 M€ (-41,6%) i.e. 8,0% of salesNet profit : 6,9 M€ (-28,6%) Adjustment of 2021/22 targets: Sales between 270 and 300 M€Current Operating Income around 24 M€ Upgraded2022/23targets: Sales between 400 and 450 M€ with a Current Operating Margin (1) >14% BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its consolidated results for 1st Half Year 2021-22 (from April 1, 2021 to September 30, 2021) as approved by its Board of directors on 29 November 2021. Consolidated in M€ - IFRS09/202109/2020 ChangeSales124,2135,8-8,5%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 51,4 41,4% 24,6 19,8% 57,3 42,2% 33,4 24,6%-10,3% -26,4%Current operating income EBITA In % of Sales Non recurrent items 9,9 8,0% (5,8)16,9 12,5% (2,3) -41,6% Operating income In % of Sales 4,1 3,3%14,7 10,8%-71,8%Financial result incl. Currency gain /(loss) incl
PRESS RELEASE: NACON: HALF-YEAR RESULTS 2021/2229.11.2021 18:56:58 CET | Press release
Nacon Press release Lesquin, 29 November 2021, 18:00 hrs HY 1 2021/22 impacted by an unfavourable basis comparison: Sales: 73.0 M€ (-15.7%)Current Operating Income: 8.4 M€ (-46.3%), i.e. 11,6% of salesNet profit: 3.8 M€ (-60.4%) Ajustmentof 2021/22targets: Sales between 150 and 180 M€Current Operating Income close to 20 M€ Upwardrevision of 2022/23targets: Sales between 250 and 300 M€ with a COI rate* > 20% NACON (ISIN FR0013482791) today releases its audited consolidated results for the first half of fiscal year 2021/22 (from April 1 to September 30) as approved by its Board of directors on 29 November 2021. Consolidated in M€ - IFRS09/202109/2020 ChangeSales73,086,6-15,7%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 38,0 52,1% 21,4 29,3% 45,3 52,3% 30,4 35,1%-16,0% -29,7%Current operating income EBITA In % of Sales Non recurrent items (including Bonus Shares)8,4 11,6% (4,0)15,7 18,2% (1,8) -46,3% Operating result In % of Sales4,5 6,1%13,9 16,1%-67,8%Financial result Includi
RCI Banque: Emtn Base Prospectus 202129.11.2021 18:30:00 CET | Press release
November 10th, 2021 RCI Banque: Emtn Base Prospectus 2021 The RCI Banque EMTN base prospectus dated November 10th 2021, is now available on the RCI Banque web site (www.rcibs.com). Attachment Communiqué de Publication RCI Banque EMTN Base Prospectus 2021 gb
RCI Banque: Emtn Base Prospectus 202129.11.2021 18:30:00 CET | Press release
November 10th, 2021 RCI Banque: Emtn Base Prospectus 2021 The RCI Banque EMTN base prospectus dated November 10th 2021, is now available on the RCI Banque web site (www.rcibs.com). Attachment RCI Banque - EMTN Update 2021 - Base Prospectus - Final(10218892813.1)
Leasinvest Real Estate NV: Minutes of the Extraordinary General Meeting of 29 November 2021 – Change of Name – Corporate Governance Charter – Executive Committee29.11.2021 17:40:00 CET | Press release
LEASINVEST REAL ESTATE NV: MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF 29 NOVEMBER 2021 – CHANGE OF NAME – CORPORATE GOVERNANCE CHARTER – EXECUTIVE COMMITTEE Minutes of the extraordinary general meeting of 29/11/2021 The legally required attendance quorum was achieved so the Extraordinary General Meeting (EGM) of 29/11/2021 was able to deliberate validly. All the proposed resolutions on the agenda were adopted, including the resolutions to change the name from Leasinvest Real Estate NV to Nextensa NV and to approve the updated remuneration policy. The minutes of the meeting provide a detailed summary of all proposed resolutions on the agenda and the votes casted regarding the resolutions and are available on the website (henceforth www.nextensa.eu) here https://nextensa.eu/en/investor-relations/general-meetings/ . In the votes, due consideration was given to the double voting rights that were introduced at the EGM of 19/07/2021, as a result of which registered shareholders listed i